A Phase 1 interventional study of RG1507 and RO1507 in Neoplasms, sponsored by Hoffmann-La Roche. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There are 3 subsets of patients who are eligible for the study: untreated, treated and requiring further treatment, or treated and failed and for whom adding R1507 represents a suitable treatment for their disease. All regimens will first test doses of R1507 which are less than the maximally administered dose, and if tolerated, the dose will be escalated in subsequent patients. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's enrollment of 104 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RG1507 · Drug: erlotinib [Tarceva] · Drug: gemcitabine
Drug: RG1507 · Drug: temozolomide
Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: docetaxel
Drug: RG1507 · Drug: pemetrexel
Drug: RO1507
Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: paclitaxel
Drug: RG1507 · Drug: carboplatin · Drug: etoposide
Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: mFOLFOX6
Drug: RG1507 · Drug: capecitabine [Xeloda] · Drug: trastuzumab [Herceptin]
Drug: RG1507 · Drug: sorafenib
Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: erlotinib [Tarceva]
Drug: RG1507 · Drug: cetuximab · Drug: irinotecan
Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: carboplatin · Drug: paclitaxel
Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
27mg/kg iv, monotherapy
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
as prescribed
Adverse events, laboratory parameters, vital signs
Time frame: Throughout study
Trough levels of R1507
Time frame: Throughout study
The record gives a start of Feb 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teprotumumab